D75.81
BillableMyelofibrosis
HCC Category Mapping
V28HCC 19 — Lymphoma and Other Cancers
0.105V24HCC 46 — Severe Hematological Disorders
0.666ESRDHCC 46 — Severe Hematological Disorders
0.000RxHCCHCC 16 — Multiple Myeloma and Plasma Cell Neoplasms
0.000What This Code Means
A condition where bone marrow becomes scarred and fibrotic, leading to reduced blood cell production and potential anemia or bleeding problems.
Coding Tips
- •Myelofibrosis can be primary or secondary; verify if this is primary myelofibrosis or secondary to another condition
- •Document the stage of myelofibrosis if available, as this affects treatment and prognosis
Clinical Significance
Myelofibrosis is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, extramedullary hematopoiesis (splenomegaly, hepatomegaly), and peripheral blood cytopenias. It may be primary (PMF) or secondary to polycythemia vera or essential thrombocythemia. The disease carries risk of transformation to acute myeloid leukemia. JAK2, CALR, or MPL driver mutations are found in approximately 90% of cases.
Documentation Requirements
- ✓Document bone marrow biopsy findings showing fibrosis grading (MF-0 to MF-3), driver mutation status (JAK2 V617F, CALR, MPL), complete blood count with differential, peripheral blood smear findings (leukoerythroblastic picture, teardrop cells), spleen size, and prognostic risk score (DIPSS, MIPSS70).
- ✓Record current treatment (JAK inhibitors like ruxolitinib, transfusion support, hydroxyurea).
Excludes 1 — Do NOT code together
Use Additional Code
Code First
- the underlying disorder, such as:
- malignant neoplasm of breast (C50.-)